March 20 (Reuters) - Arovella Therapeutics Ltd (ALA) :
- ALA-101 AND ONCARLYTICS COLLABORATION UPDATE
- IMUGENE HAS ADVISED AROVELLA THAT IT NO LONGER WISHES TO CONTINUE COLLABORATION
- PARTNERSHIP TO COMBINE ALA‐101 AND ONCARLYTICS HAS ENDED
- NO FINANCIAL IMPACT FROM CESSATION OF COLLABORATION FOR AROVELLA
- COLLABORATION WILL BE TERMINATED WITH IMMEDIATE EFFECT
- TERMINATION WILL NOT IMPACT CO'S DEVELOPMENT OF ALA‐101 FOR CD19‐POSITIVE BLOOD CANCERS
(([email protected];;))
News: ALA Arovella Therapeutics Gives ALA-101 And Oncarlytics Collaboration Update
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $124.8M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $21.83K | 212.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 443503 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 424264 | 6 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| ALA (ASX) Chart |